Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
15 bookmarks, we need more peeps following this stock. QB stock full of potentials and intl opportunities no reason not to reach one dollar per share.
Yes, China, Vietnam, Cambodia, Laos, Australia, New Zealand:
For China, the Company entered into an exclusive distribution agreement with the Yinzhou Police
Equipment & Technology Co., Ltd. (Guangzhou, China) for its PCT product line and a non-exclusive
agreement for its patent-pending, mechanical homogenization device, the Shredder SG3, and associated
consumables. This Agreement allows Yinzhou to market and sell PBI products into the forensics
marketplace only. PBIO plans to add one or more additional distributors in China for representation
outside of the forensics area during the second half of 2012.
For Vietnam, Cambodia, and Laos, the Company entered into an exclusive distribution agreement with
BMN MSI., Ltd. (Hanoi, Vietnam) for its PCT product line and a non-exclusive agreement for the
Shredder SG3 homogenization device and associated consumables.
For Australia and New Zealand, the Company entered into an exclusive distribution agreement with
iScience Technology (Melbourne, Australia) for its PCT product line, and a non-exclusive agreement for
the Shredder SG3 homogenization device and associated consumables.
checkin L2 now, I think 0.5 is not that far away. Lets see 0.5 this week!
fyi http://www.otcmarkets.com/stock/PBIO/quote shows L2
PR yesterday: High Growth Expected for 2013 and Beyond
Another Strong Quarter of Product Sales is Expected
After booking record sales of PCT products in third quarter of 2012, we are expecting another strong quarter of product sales for fourth quarter of 2012.
We estimate product sales of $0.32 million for the fourth quarter of 2012, a 79% increase compared to $0.18 million product sales of 4Q11. These product sales include PCT equipment and consumables.
Grant revenue is expected to be $0.10 million for 4Q12, compared to $0.16 million for 4Q11.
Total revenue based on our estimate will be $0.42 million for the fourth quarter of 2012, compared to $0.34 million for the fourth quarter of 2011, an increase of 25%.
Gross margin for product sales is estimated to be 65.6% for the 4Q12, compared to 48.5% for the 4Q11, a 35% improvement.
Operating loss is expected to be $0.7 million for the 4Q12, compared to operating loss of $0.9 million for 4Q11, a 22% improvement.
We estimate that net loss will be $0.9 million or $0.08 per share, compared to net loss of $2.0 million or $0.30 per share.
Based on the improvements of financial results for the last three quarters of 2012, and the aggressive commercialization strategy the Company has implemented in 2012, we expect revenue will enter into high growth in 2013 and beyond. From 2012 to 2015, net product sales will grow at amazing 118% compound annual growth rate (CAGR). PBIO will become profitable in fiscal 2015 with EPS of $0.06 based on total revenue of $11 million.
We think the share price of PBIO is undervalued. At this time, the downside risk is low while upside potential is high for the Company.
Leadership Strengthened by Appointing New Chief Financial Officer
On December 5, 2012, Pressure BioSciences, Inc. (OTC Markets:PBIO) announced that Mr. Conrad F. Mir has joined the Company as its chief financial officer, effective immediately.
Mr. Mir has over twenty years experience in investment banking, financial structuring, and corporate reengineering. He has served in various executive management roles and on the Board of Directors of several companies in the biotechnology industry. Most recently, Mr. Mir was chairman and CEO of Genetic Immunity, Inc. (:GI), a plasmid, DNA company in the HIV space. Prior to GI, Mr. Mir served as executive director of Advaxis, Inc., a vaccine company. During his tenure at GI and Advaxis, Mr. Mir was responsible for raising nearly $40 million in growth capital and broadening corporate reach to new investors and current shareholders.
Prior to GI and Advaxis, Mr. Mir worked for several investment banks including Sanford C. Bernstein, First Liberty Investment Group, and Nomura Securities International. He holds a BA/BS in Economics and English with special concentrations in Mathematics and Physics from New York University.
PBIO recently announced record PCT product sales for the third quarter of 2012, and we expect another strong quarter of product sales for the 4Q12. The Company has implemented aggressive commercialization strategy in 2012 to accelerate the revenue growth of its patented PCT products and services which included, among other things, an increase in international sales and distribution coverage from three to over twenty countries. But PBIO needs to properly finance this initiative. This is currently the biggest concern.
We believe the strong investment banking background of Mr. Mir will help PBIO raise new capital to fund its operations. It is also one of Conrad’s best strengths. He has proven over the past few years that he has the ability to raise significant funds for small, developing companies in a smart and timely way.
................
see news on this link:
http://finance.yahoo.com/news/pressure-biosciences-pbio-high-growth-152335014.html
News out, did you see it?
Most undervalued OTC QB on planet! get in now!!!
I see $1 SOON!
this news is awesome just a matter of time and kabooommmmm!
the share price of PBIO is undervalued. At this time, the downside risk is low while upside potential is high for the Company.
Finally PR, see yahoo
Morning guys! PBIO Rock$
yes, recession proof industries it seems.
"counter-bioterror" industry alone is a multi Billion industry, Defense ministry got no limit on their budget you know. Countless oppportunitites here. imo
PBIO News will be huge, lets see it. time is near!
uptrend no doubt! $1 possible here: RADAR!
There were several announcements last month i expect this month to be no different. So we might get more than one PR, but i also think we get a huge PR!!
thanks C. should be anytime now, right? lets get this party started!
Edou, wondering what developments can we expect as 'PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for forensics, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, histology, and counter-bioterror applications.'
Excited to see that PR edou777, this is a hidden gem!
have a good weekend!
Thanks for posting it again. What more can you want? A penny stock that has a REAL product that is generating REAL revenue!! And they have Soo much coming up. This is truly going to be a cash cow and they seem to have the capabilities to go out and GET JOBS/CONTRACTS.
NYSe : TMO 26BILLION MKT CAP company! trades @ $73 !
PBIO is offering similar services products. there is long way to go but it tells me huge potentials in this industry!
CAsto,are you talking about Barocycler, right? great product!
Castorama, fyi, there is a Scientific Meeting coming up where PBI to showcase the Barocycler HUB440 System, the Company’s newest high pressure generator, and its many applications in bioscience, and Constant Systems cell disruption equipment at the 2013 US HUPO Annual Conference
March 10 - 13, 2013 in Baltimore, MD
GM, www.pressurebiosciences.com
Even Real-Time Level 2 Quote Montage is available on otcmarkets.com , good standing otcQB company!
PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
to become a vital sample preparation tool to research and clinical laboratories worldwide.
This it folks Worldwide! company got overseas money coming in thats the name of the game
Yes, PCT technology uses instrumentation that cycles pressure between ambient and ultra-high levels at controlled temperatures to control the interactions of bio-molecules. It offers Barocycler instrumentation products, including Barocycler NEP3229 Barocycler that processes up to three samples simultaneously using its single-use PULSE Tubes; and Barocycler NEP2320, which processes one sample at a time and works on compressed air.
Indeed, potentials are endless here!!
Need a PR and then rock and roll, imo
GM, good times might just return, i hope!
Agreed, looking good!
AMEN to that! DECEMBER 21 2012. No End of World here.. in fact, a new beginning for SNTL!
.20++ coming no doubt about that!
Golden Cross soon. weeee. Chart analyzers will love it and join the party here.
SNTL
SYNCRONYS is doing well, in fact, ready to PR huge developments,
im lovin' it!
huge funds involved, company will inform us soon , just wait and see!
SNTL
no, you dont get it. no dilution here! low float, up we go!
These Announcements are on the way, mergers and contracts are expected here. stay tuned!
Uplisting to OTC BB is on the way! the beginning of solid company developments!
Company developments will take us to the next level. Syncronys will surprise us with huge announcements.
SNTL